Skip to content

Study · Randomized controlled trial · 2022

6 results

Eating behavior modulates the sensitivity to the central effects of GLP-1 receptor agonist treatment: a secondary analysis of a randomized trial.

van Ruiten CC, Ten Kulve JS, van Bloemendaal L, Nieuwdorp M, Veltman DJ, IJzerman RG

Psychoneuroendocrinology11 Jan 2022Cited by 24 (Europe PMC)

PMID35033928 (opens in a new tab)DOI10.1016/j.psyneuen.2022.105667 (opens in a new tab)PepBankPUB-35033928
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In people with obesity and type 2 diabetes, higher emotional eating scores were associated with smaller liraglutide-induced reductions in brain responses to food pictures in the amygdala, insula and caudate nucleus after 10 days.

    In plain wordsIn people with obesity and diabetes, higher emotional eating scores were linked to a weaker brain response to liraglutide to food pictures after 10 days.

    Peptide
    Liraglutide
    Outcome
    Not applicableBrain responses to food pictures by emotional eating score (day 10)
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Appetite and food intake · Nervous system and cognition
    Studied dose
    Dose not stated · 10 daysAs given in this study (human).

    Source sentences

    Summary
    After 10 days, higher emotional eating scores were associated with less pronounced GLP-1RA induced reductions in brain responses to food pictures in the amygdala, insula and caudate nucleus.
    2 context sentences
    Summary · context
    This secondary analysis of a randomized crossover study in people with obesity and type 2 diabetes, consisted of two periods of 12-week treatment with liraglutide or insulin glargine.
    Summary · context
    Using functional MRI, we assessed the relation between baseline eating behavior and the effects of the GLP-1RA liraglutide compared with insulin after 10 days and 12 weeks of treatment on brain responses to food cues.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In people with obesity and type 2 diabetes, higher emotional eating scores tended to be associated with smaller liraglutide-induced increases in brain responses to chocolate milk receipt in the caudate nucleus and insula after 10 days.

    In plain wordsIn people with obesity and diabetes, higher emotional eating scores tended to be linked to a weaker brain response to liraglutide when receiving chocolate milk.

    Peptide
    Liraglutide
    Outcome
    Not applicableBrain responses to chocolate milk receipt by emotional eating score (day 10)
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Appetite and food intake · Nervous system and cognition
    Studied dose
    Dose not stated · 10 daysAs given in this study (human).

    Source sentences

    Summary
    In addition, higher emotional eating scores tended to be associated with less pronounced GLP-1RA increases in brain responses to chocolate milk receipt in the caudate nucleus and insula.
    2 context sentences
    Summary · context
    This secondary analysis of a randomized crossover study in people with obesity and type 2 diabetes, consisted of two periods of 12-week treatment with liraglutide or insulin glargine.
    Summary · context
    Using functional MRI, we assessed the relation between baseline eating behavior and the effects of the GLP-1RA liraglutide compared with insulin after 10 days and 12 weeks of treatment on brain responses to food cues.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In people with obesity and type 2 diabetes, emotional eating scores were not significantly associated with liraglutide-induced changes in brain responses to food cues after 12 weeks.

    In plain wordsIn people with obesity and diabetes, emotional eating scores were not linked to liraglutide's effect on brain responses to food cues after 12 weeks.

    Peptide
    Liraglutide
    Outcome
    No significant changeBrain responses to food cues by emotional eating score (week 12)
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Appetite and food intake · Nervous system and cognition
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    After 12 weeks, there were no significant associations between emotional eating scores and liraglutide-induced changes in brain responses to food cues.
    2 context sentences
    Summary · context
    This secondary analysis of a randomized crossover study in people with obesity and type 2 diabetes, consisted of two periods of 12-week treatment with liraglutide or insulin glargine.
    Summary · context
    Using functional MRI, we assessed the relation between baseline eating behavior and the effects of the GLP-1RA liraglutide compared with insulin after 10 days and 12 weeks of treatment on brain responses to food cues.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In people with obesity and type 2 diabetes, higher baseline external eating scores were associated with smaller liraglutide-induced reductions in brain responses to food pictures in the insula, amygdala and orbitofrontal cortex after 10 days.

    In plain wordsIn people with obesity and diabetes, higher external eating scores were linked to a weaker brain response to liraglutide to food pictures after 10 days.

    Peptide
    Liraglutide
    Outcome
    Not applicableBrain responses to food pictures by external eating score (day 10)
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Appetite and food intake · Nervous system and cognition
    Studied dose
    Dose not stated · 10 daysAs given in this study (human).

    Source sentences

    Summary
    After 10 days, baseline external eating scores were associated with less pronounced GLP-1RA induced reductions in brain responses to food pictures in the insula, amygdala and orbitofrontal cortex.
    2 context sentences
    Summary · context
    This secondary analysis of a randomized crossover study in people with obesity and type 2 diabetes, consisted of two periods of 12-week treatment with liraglutide or insulin glargine.
    Summary · context
    Using functional MRI, we assessed the relation between baseline eating behavior and the effects of the GLP-1RA liraglutide compared with insulin after 10 days and 12 weeks of treatment on brain responses to food cues.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In people with obesity and type 2 diabetes, higher baseline restraint eating scores were associated with larger liraglutide-induced reductions in brain responses to food pictures in the insula and caudate nucleus after 12 weeks.

    In plain wordsIn people with obesity and diabetes, higher restraint eating scores were linked to a stronger brain response to liraglutide to food pictures after 12 weeks.

    Peptide
    Liraglutide
    Outcome
    Not applicableBrain responses to food pictures by restraint eating score (week 12)
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Appetite and food intake · Nervous system and cognition
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    After 12 weeks, baseline restraint eating scores were associated with more GLP-1RA induced reductions in brain responses to food pictures in the insula and caudate nucleus, and with more GLP-1RA induced reductions in brain responses to the anticipation of chocolate milk in the caudate nucleus.
    2 context sentences
    Summary · context
    This secondary analysis of a randomized crossover study in people with obesity and type 2 diabetes, consisted of two periods of 12-week treatment with liraglutide or insulin glargine.
    Summary · context
    Using functional MRI, we assessed the relation between baseline eating behavior and the effects of the GLP-1RA liraglutide compared with insulin after 10 days and 12 weeks of treatment on brain responses to food cues.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In people with obesity and type 2 diabetes, higher baseline restraint eating scores were associated with larger liraglutide-induced reductions in brain responses to anticipation of chocolate milk in the caudate nucleus after 12 weeks.

    In plain wordsIn people with obesity and diabetes, higher restraint eating scores were linked to a stronger brain response to liraglutide while expecting chocolate milk.

    Peptide
    Liraglutide
    Outcome
    Not applicableBrain responses to anticipation of chocolate milk by restraint eating score (week 12)
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Appetite and food intake · Nervous system and cognition
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    After 12 weeks, baseline restraint eating scores were associated with more GLP-1RA induced reductions in brain responses to food pictures in the insula and caudate nucleus, and with more GLP-1RA induced reductions in brain responses to the anticipation of chocolate milk in the caudate nucleus.
    2 context sentences
    Summary · context
    This secondary analysis of a randomized crossover study in people with obesity and type 2 diabetes, consisted of two periods of 12-week treatment with liraglutide or insulin glargine.
    Summary · context
    Using functional MRI, we assessed the relation between baseline eating behavior and the effects of the GLP-1RA liraglutide compared with insulin after 10 days and 12 weeks of treatment on brain responses to food cues.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.